Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1394-1401

  Zeng, Lihua ^a,b   Kizaka Kondoh, Shinae ^a   Itasaka, Satoshi ^a   Xie, Xuejun ^b   Inoue, Masahiro ^c   Tanimoto, Keiji ^d   Shibuya, Keiko ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MICROTUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SURVIVAL RATE; WESTERN BLOTTING;

ANIMALS; CELL LINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; PROTEIN CONFORMATION; TUBULIN; TUBULIN MODULATORS;

EID: 34547777468     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00537.x     Document Type: Article

References (46)

1. Miller ML, Ojima I. Chemistry and chemical biology of Taxane anticancer agents. Chem Record 2001; 1: 195-211.
2. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: Myths and reality (a critical review). Int J Cancer 1999; 83: 151-6.
3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979; 277: 665-7.
4. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17: 1061-70.
5. Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance: Molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3: 1-19.
6. Sangrajranga S, Fellousb A. Taxol resistance. Chemotherapy 2000; 46: 327-34.
7. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65: 9021-8.
8. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363-75.
9. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan S. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387-94.
10. Unruh A, Ressel A, Mohamed HG, et. al. The hypoxia-inducible factor-1 is a negative factor for tumor therapy. Oncogene 2003; 22: 3213-20.
11. Erler JT, Cawthorne CJ, Williams KJ, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via HIF-1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004; 24: 2875-89.
12. Semanza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
13. Brown JM, Wilson WR. Exploring tumor hypoxia in cancer treatment. Nat Rev Cancer 2004; 4: 437-47.
14. Kurokawa T, Miyamoto M, Kato K, et al. Overexpression of hypoxia-inducible-factor 1 alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 2003; 89: 1042-7.
15. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1 alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005; 11: 1129-35.
16. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, O'Byrne KJ. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathway. Int J Cancer 2004; 111: 43-50.
17. Fillies T, Werkmeister R, Van Diest PJ, Brandt B, Joos U, Buerger H. HIF 1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005; 5: 84-92.
18. Brown LM, Cowen RL, Debray C, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 2006; 69: 411-18.
19. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003; 22: 3213-20.
20. Huang L, Ao QL, Li F, Xing H, Lu YP. Impact of hypoxia on taxol-induced apoptosis in human ovarian cancer cell line A2780 and its mechanism. Ai Zheng 2005; 24: 408-13.
21. Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000; 6: 957-65.
22. Li L-M, Lin X-Y, Staver M, et al. Evaluating hypoxia-inducible factor-1 as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-58.
23. Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 2005; 4: 182-93.
24. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003; 9: 5532-9.
25. Rahat MA, Marom B, Bitterman H, Weiss-Cerem L, Kinarty A, Lahat N. Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association. J Leukoc Biol 2006; 79: 706-18.
26. Yoon S-O, Shin S, Mercurio AM. Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the 6β4 integrin. Cancer Res 2005; 65: 2761-9.
27. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995; 1: 506-26.
28. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 1994; 54: 4355-61.
29. Lin HL, Chang YF, Liu TY, Wu CW, Chi CW. Submicromolar paclitaxel induces apoptosis in human gastric cancer cells at early G1 phase. Anticancer Res 1998; 18: 3443-9.
30. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996; 88: 1308-14.
31. Milas L, Hunter NR, Kurdoglu B et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 1995; 35: 297-303.
32. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 1997; 94: 9679-83.
33. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: Induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998; 95: 3896-901.
34. Blagosklonny MV, Giannakakou P, el-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res 1997; 57: 130-5.
35. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92: 4507-11.
36. Horwitz SB, Liao LL, Greenberger L, et al. Mode of action of Taxol and characterization of multidrug-resistant cell line resistant to Taxol. In: Kessel D, ed. Resistance to Antineoplastic Drugs. Boca Raton, FL: CRC Press, 1989; 109-26.
37. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5: 457-68.
38. Lorico A, Rappa G, Flavell RA, et al. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res 1996; 56: 5351-5.
39. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1a. Gene Dev 2000; 14: 34-44.
40. Hansson LO, Friedler A, Freund S, et al. Two sequence motifs from HIF-1 alpha bind to the DNA-binding site of p53. Proc Natl Acad Sci USA 2002; 99: 10 305-9.
41. Chen D, Li M, Luo J, et al. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 2003; 278: 13 595-8.
42. An WG, Kanekal M, Simon MC, et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha. Nature 1998; 392: 405-8.
43. Lai S-L, Perng R-P, Hwang J. p53 Gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 2000; 7: 64-70.
44. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 2003; 42: 5349-57.
45. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist Updat 2001; 4: 3-8.
46. Jordan MA, Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10: 123-30.